Physician profile
Fasil Mathews
NPI 1922661305
$3,576.74
in general payments reported to CMS, 2019-2025
21 companies · $3,012 in 2025
The $3,012 reported for 2025 was more than what 93% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $565 · 2025: $3,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,565 · Travel and Lodging: $1,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,565.22 |
| Travel and Lodging | $1,011.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerin Medical INC. | $1,736.95 | 2024-2025 | |
| Integra Lifesciences Corporation | $311.20 | 2025 | Acclarent Aera, Trudi Probe, Inspira Air |
| Genzyme Corporation | $286.81 | 2024-2025 | |
| Medtronic, INC. | $171.65 | 2025 | Pteye Parathyroid Detection System |
| Glaxosmithkline, LLC. | $162.71 | 2024-2025 | Nucala, Trelegy Ellipta |
| Neurent Medical Limited | $119.77 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Grifols USA, LLC | $114.00 | 2025 | Xembify |
| Optinose US, INC. | $97.46 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $83.47 | 2025 | Dupixent |
| Stryker Corporation | $61.13 | 2025 | Xpress Loprofile, Audion Et Dilation System, Scopis Ent |
| Blueprint Medicines Corporation | $58.72 | 2024 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $57.39 | 2024-2025 | Cuvitru |
| Hikma Pharmaceuticals USA | $50.50 | 2024 | Ryaltris |
| 3nt Medical | $49.68 | 2024 | |
| Novartis Pharmaceuticals Corporation | $48.19 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $44.35 | 2024 | Acupulse Duo |
| Astrazeneca Pharmaceuticals LP | $37.08 | 2024-2025 | Tezspire |
| Paratek Pharmaceuticals, INC. | $30.73 | 2025 | Xhance |
| Csl Behring | $20.24 | 2025 | Hizentra |
| Kaleo, INC. | $18.88 | 2024 | Auvi-Q |
| Freudenberg Medical, LLC | $15.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fasil Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.